Pomalidomide: New immunomodulatory agent with potent antiproliferative effects

Paul G. Richardson, Tomer M. Mark, Martha Lacy

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

New treatment options are urgently needed for patients with relapsed multiple myeloma (MM) who are refractory to thalidomide, lenalidomide, and bortezomib therapy. Pomalidomide, a second-generation immunomodulatory agent, has been shown to exert direct antiproliferative actions on MM cells, effects on the bone-marrow microenvironment, and immunomodulation. In phase I clinical trials, pomalidomide has demonstrated promising response rates in patients with relapsed and/or refractory MM, with manageable toxicity. In phase II trials pomalidomide, 2-4. mg/daily, given continuously or on days 1-21 of a 28-day cycle, in combination with dexamethasone, has been associated with high quality and durable clinical responses in patients who are refractory to lenalidomide, bortezomib, or both. Pomalidomide appears to be well tolerated; hematologic toxicities are the most commonly reported adverse events and peripheral neuropathy is rare. Phase III trials are currently underway to determine the optimal dose and combination regimen of pomalidomide in the treatment of MM.

Original languageEnglish (US)
JournalCritical Reviews in Oncology/Hematology
Volume88
Issue numberSUPPL.1
DOIs
StatePublished - Oct 1 2013

Fingerprint

Multiple Myeloma
Clinical Trials, Phase I
Thalidomide
Immunomodulation
Peripheral Nervous System Diseases
Dexamethasone
Therapeutics
Bone Marrow
pomalidomide
Bortezomib
lenalidomide

Keywords

  • Immunomodulatory agent
  • Multiple myeloma
  • Pomalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

Pomalidomide : New immunomodulatory agent with potent antiproliferative effects. / Richardson, Paul G.; Mark, Tomer M.; Lacy, Martha.

In: Critical Reviews in Oncology/Hematology, Vol. 88, No. SUPPL.1, 01.10.2013.

Research output: Contribution to journalReview article

@article{ad1ab34ca6c14922b972a619c711d785,
title = "Pomalidomide: New immunomodulatory agent with potent antiproliferative effects",
abstract = "New treatment options are urgently needed for patients with relapsed multiple myeloma (MM) who are refractory to thalidomide, lenalidomide, and bortezomib therapy. Pomalidomide, a second-generation immunomodulatory agent, has been shown to exert direct antiproliferative actions on MM cells, effects on the bone-marrow microenvironment, and immunomodulation. In phase I clinical trials, pomalidomide has demonstrated promising response rates in patients with relapsed and/or refractory MM, with manageable toxicity. In phase II trials pomalidomide, 2-4. mg/daily, given continuously or on days 1-21 of a 28-day cycle, in combination with dexamethasone, has been associated with high quality and durable clinical responses in patients who are refractory to lenalidomide, bortezomib, or both. Pomalidomide appears to be well tolerated; hematologic toxicities are the most commonly reported adverse events and peripheral neuropathy is rare. Phase III trials are currently underway to determine the optimal dose and combination regimen of pomalidomide in the treatment of MM.",
keywords = "Immunomodulatory agent, Multiple myeloma, Pomalidomide",
author = "Richardson, {Paul G.} and Mark, {Tomer M.} and Martha Lacy",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.critrevonc.2013.02.001",
language = "English (US)",
volume = "88",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL.1",

}

TY - JOUR

T1 - Pomalidomide

T2 - New immunomodulatory agent with potent antiproliferative effects

AU - Richardson, Paul G.

AU - Mark, Tomer M.

AU - Lacy, Martha

PY - 2013/10/1

Y1 - 2013/10/1

N2 - New treatment options are urgently needed for patients with relapsed multiple myeloma (MM) who are refractory to thalidomide, lenalidomide, and bortezomib therapy. Pomalidomide, a second-generation immunomodulatory agent, has been shown to exert direct antiproliferative actions on MM cells, effects on the bone-marrow microenvironment, and immunomodulation. In phase I clinical trials, pomalidomide has demonstrated promising response rates in patients with relapsed and/or refractory MM, with manageable toxicity. In phase II trials pomalidomide, 2-4. mg/daily, given continuously or on days 1-21 of a 28-day cycle, in combination with dexamethasone, has been associated with high quality and durable clinical responses in patients who are refractory to lenalidomide, bortezomib, or both. Pomalidomide appears to be well tolerated; hematologic toxicities are the most commonly reported adverse events and peripheral neuropathy is rare. Phase III trials are currently underway to determine the optimal dose and combination regimen of pomalidomide in the treatment of MM.

AB - New treatment options are urgently needed for patients with relapsed multiple myeloma (MM) who are refractory to thalidomide, lenalidomide, and bortezomib therapy. Pomalidomide, a second-generation immunomodulatory agent, has been shown to exert direct antiproliferative actions on MM cells, effects on the bone-marrow microenvironment, and immunomodulation. In phase I clinical trials, pomalidomide has demonstrated promising response rates in patients with relapsed and/or refractory MM, with manageable toxicity. In phase II trials pomalidomide, 2-4. mg/daily, given continuously or on days 1-21 of a 28-day cycle, in combination with dexamethasone, has been associated with high quality and durable clinical responses in patients who are refractory to lenalidomide, bortezomib, or both. Pomalidomide appears to be well tolerated; hematologic toxicities are the most commonly reported adverse events and peripheral neuropathy is rare. Phase III trials are currently underway to determine the optimal dose and combination regimen of pomalidomide in the treatment of MM.

KW - Immunomodulatory agent

KW - Multiple myeloma

KW - Pomalidomide

UR - http://www.scopus.com/inward/record.url?scp=84882612996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882612996&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2013.02.001

DO - 10.1016/j.critrevonc.2013.02.001

M3 - Review article

C2 - 23786844

AN - SCOPUS:84882612996

VL - 88

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - SUPPL.1

ER -